Confidential Disclosure Agreements definition

Confidential Disclosure Agreements means (i) the Confidential Disclosure Agreement between the Parties dated September 16, 2004, as amended by the Amendment to Confidential Disclosure Agreement dated October 29, 2004 and the Second Amendment to Confidential Disclosure Agreement dated February 1, 2005; (ii) the Confidential Disclosure Agreement between the Parties dated February 1, 2005 (JT as recipient); and (iii) the Confidential Disclosure Agreement between the Parties dated February 1, 2005 (Gilead as recipient).

Split View

AI-Powered Contracts

Draft, Review & Redline at the Speed of AI

Get StartedBook a Demo

Confidential Disclosure Agreements means all Mutual Non-Disclosure Agreements previously or hereafter entered into by certain Integra Affiliates and PcoMed.

Confidential Disclosure Agreements means, [***].

Examples of Confidential Disclosure Agreements in a sentence

• If Company and Penn entered into one or more Confidential Disclosure Agreements prior to the Effective Date, then such agreements will continue to govern the protection of confidential information under this Agreement, and each Affiliate and sublicensee of Company will be bound to Company’s obligations under such agreements.

• The term “Confidentiality Agreement” means all Confidential Disclosure Agreements between the parties that remain in effect after the Effective Date.

• If any Confidential Disclosure Agreements have been executed, such Agreements are incorporated herein by reference.

• The parties acknowledge that the Confidential Disclosure Agreement dated as of October 8, 2002 between Fluidigm and Oculus and the Confidential Disclosure Agreement dated December 19, 2002 between Fluidigm, Oculus and UABRF are binding upon the parties hereto and in full force and effect, except to the extent that the provisions hereof supersede provisions to similar effect contained in the Confidential Disclosure Agreements.

• Upon any termination of this Agreement, all parties hereto shall be relieved of all further obligations under this Agreement, except for the provisions of Section 2.5 regarding the assignment by Oculus to Fluidigm of Assigned Rights, together with all patent rights and all other intellectual property rights therein, Section 15.6 regarding the payment of certain expenses and Section 10.1 regarding the continuing obligations of the parties under the Confidential Disclosure Agreements.

• The terms of the Confidential Disclosure Agreements (exclusive of such superseded provisions) are incorporated in this Agreement by this reference.

• The term “Confidentiality Agreement” means all Confidential Disclosure Agreements between the parties that remain in effect after the Effective Date, and the term “Confidential Information” refers to confidential or proprietary information thereunder.

• Buyer shall reimburse Seller Parties for any documented out-of-pocket expenses incurred in connection with the enforcement of such rights pursuant to this Section 2.10 (Confidential Disclosure Agreements).

• If Company and Penn entered into one or more Confidential Disclosure Agreements prior to the Restatement Date, then such agreements will continue to govern the protection of confidential information under this Agreement, and each Affiliate and sublicensee of Company will be bound to Company’s obligations under such agreements.

• If the Parties have communicated Confidential Information pertinent to the Early Access Program to each other pursuant to Confidential Disclosure Agreements and/or Non-Disclosure Agreements, prior to the Effective Date, all such Confidential Information transmitted, received, or exchanged will be governed by this Agreement, which shall supersede any such other agreements in their application to Confidential Information relating to the Program.

More Definitions of Confidential Disclosure Agreements

Confidential Disclosure Agreements means, collectively, the Mutual Confidentiality Agreement dated as of August 15, 2022, by and between Gurnet Point Capital, LLC and the Company and the Nondisclosure and Confidentiality Agreement dated as of January 6, 2023, by and between Gurnet Point Capital, LLC, Novo Holdings Equity US Inc. and the Company.

Confidential Disclosure Agreements. Subject: Andrographolide and a proprietary screening technology Effective Date: August 25, 1995 Subject: Kinases and therapeutic inhibitors of cellular kinases involved in Human Immunodeficiency Virus growth. Effective Date: September 4, 1995 Subject: Role of certain signal transduction pathways in malignant cell growth and in cell death" Effective Date: July 2, 1996 LICENSES: Paracelsian is currently negotiating the terms of a Biological Material License with the Office of Technology Transfer, NIH, for the use of cell lines HIVenv(2-8) and (2-2) developed by ▇▇. ▇▇▇▇▇ while working for NIAID. These cell lines were created prior to the effective date of the CRADA, and as such are not a Subject Invention under the CRADA. Abstract FOR PUBLIC RELEASE of the Research Plan of the CRADA The principal goals of this proposed CRADA involve the screening of a library of traditional Chinese medicines (TCMs) for their affects on reducing HIV induced cytotoxicity and /or their ability to inhibit cell growth in various tumor cell lines. It is hoped that this CRADA will lead to new drug designs for future anti-HIV and anti-cancer therapy. Thus, the specific objectives of this CRADA will be: